journal
MENU ▼
Read by QxMD icon Read
search

Breast Cancer Research and Treatment

journal
https://www.readbyqxmd.com/read/28646345/increasing-utilization-of-regional-nodal-irradiation-in-elderly-node-positive-women-and-declining-emphasis-on-demographic-factors
#1
Jason K Molitoris, Tejan Diwanji, James W Snider, Emily C Bellavance, Susan B Kesmodel, Paula Rosenblatt, Katherine Tkaczuk, Soren M Bentzen, Randi J Cohen, Elizabeth M Nichols, Sally B Cheston, Steven J Feigenberg
PURPOSE: To evaluate the practice patterns for the use of regional nodal irradiation (RNI) in treatment of elderly women with low volume node-positive breast cancer in the setting of breast conservation surgery (BCS). METHODS: Women aged 70-89 diagnosed with unilateral, pathologic T1-2N1M0 breast cancer from 2004 to 2013, who underwent BCS and received radiotherapy were identified from the National Cancer Database. In 2011, two major trials were presented that helped define indications for RNI...
June 23, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28646344/does-biomarker-information-impact-breast-cancer-patients-preferences-and-physician-recommendation-for-adjuvant-chemotherapy
#2
Ann H Partridge, Karen Sepucha, Anne O'Neill, Kathy D Miller, Emily Baker, Chau T Dang, Donald W Northfelt, George W Sledge, Bryan P Schneider
PURPOSE: This study aimed to examine how biomarker information would impact patients' preferences and physicians' recommendations for adjuvant breast cancer therapy. METHODS: At the 18-month follow-up, participants in a large, double-blind randomized controlled trial of adjuvant chemotherapy with bevacizumab or placebo (E5103) were surveyed about their preferred treatment (either chemotherapy A alone or chemotherapy A+B) in two hypothetical scenarios: (1) without biomarker information; and (2) after learning that they tested positive for a "B-receptor" which modestly increased both the benefit and toxicity expected with chemotherapy A+B...
June 23, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28643023/variable-aromatase-inhibitor-plasma-concentrations-do-not-correlate-with-circulating-estrogen-concentrations-in-post-menopausal-breast-cancer-patients
#3
Daniel L Hertz, Kelly A Speth, Kelley M Kidwell, Christina L Gersch, Zeruesenay Desta, Anna Maria Storniolo, Vered Stearns, Todd C Skaar, Daniel F Hayes, N Lynn Henry, James M Rae
PURPOSE: The aromatase inhibitors (AI) exemestane (EXE), letrozole (LET), and anastrozole suppress estrogen biosynthesis, and are effective treatments for estrogen receptor (ER)-positive breast cancer. Prior work suggests that anastrozole blood concentrations are associated with the magnitude of estrogen suppression. The objective of this study was to determine whether the magnitude of estrogen suppression, as determined by plasma estradiol (E2) concentrations, in EXE or LET treated patients is associated with plasma AI concentrations...
June 22, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28643022/androgen-receptor-expression-and-breast-cancer-mortality-in-a-population-based-prospective-cohort
#4
Karin Elebro, Pär-Ola Bendahl, Helena Jernström, Signe Borgquist
PURPOSE: The increase in clinical trials with androgen receptor (AR)-targeting drugs emphasizes the need of clarifying the role of AR expression in different breast cancer subtypes. AR confers good prognosis in estrogen receptor positive (ER+) breast cancer, but its role in ER-negative (ER-) breast cancer is unclear. The aim of this study was to elaborate on previous findings of a differential prognostic role for AR depending on ER status, using breast cancer mortality (BCM) as endpoint, in a population-based cohort from the Malmö Diet and Cancer Study...
June 22, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28643021/the-effect-of-14-3-3%C3%AE-expression-on-tamoxifen-resistance-and-breast-cancer-recurrence-a-danish-population-based-study
#5
Jake E Thistle, Ylva Hellberg, Kristina Mortensen, Stephen Hamilton-Dutoit, Anders Kjærsgaard, Deirdre Cronin-Fenton, Henrik Toft Sørensen, Timothy L Lash
PURPOSE: Overexpression of 14-3-3ζ has been linked to breast cancer recurrence in several studies, including studies assessing its effect on tamoxifen resistance. The study was performed to estimate the effect of 14-3-3ζ and differentiate potential prognostic or predictive utility. METHODS: A case-control study, nested in a population of 11,251 females residing on the Jutland Peninsula of Denmark, was performed. Participants were aged 35-69, diagnosed with stage I, II, or III breast cancer between 1985 and 2001, and registered with the Danish Breast Cancer Cooperative Group...
June 22, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28643020/association-between-lifestyle-menstrual-reproductive-history-and-histological-factors-and-risk-of-breast-cancer-in-women-biopsied-for-benign-breast-disease
#6
Rhonda Arthur, Yihong Wang, Kenny Ye, Andrew G Glass, Mindy Ginsberg, Olivier Loudig, Thomas Rohan
PURPOSE: Women with benign breast disease (BBD) have an increased risk of subsequent breast cancer. However, whether conventional breast cancer risk factors influence risk of breast cancer among women with BBD is unclear. In this study, we investigated the associations of lifestyle, menstrual/reproductive, and histological factors with risk of breast cancer among women biopsied for BBD. METHODS: We conducted a case-control study, nested within a cohort of 15,395 women biopsied for BBD at Kaiser Permanente Northwest between 1971 and 2006...
June 22, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28643019/antibody-based-therapies-for-the-treatment-of-brain-metastases-from-her2-positive-breast-cancer-time-to-rethink-the-importance-of-the-bbb
#7
LETTER
Vasileios Askoxylakis, David P Kodack, Gino B Ferraro, Rakesh K Jain
No abstract text is available yet for this article.
June 22, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28639031/opioid-use-among-female-breast-cancer-patients-using-different-adjuvant-endocrine-therapy-regimens
#8
Xi Tan, Tareq Fabian Camacho, Virginia T LeBaron, Leslie J Blackhall, Rajesh Balkrishnan
PURPOSE: To explore differences in opioid use across different adjuvant endocrine therapy (AET) regimens, factors associated with opioid use, and the impact of opioid use on overall survival in female breast cancer patients treated with AET. METHODS: This retrospective study analyzed 2006-2012 SEER-Medicare datasets, following patients for at least two years from the index date, defined as the first date they filled an AET prescription. The study included adult women with incident, primary, hormone-receptor-positive, stage I-III breast cancer...
June 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28639030/utilization-of-hypofractionated-whole-breast-radiation-therapy-in-patients-receiving-chemotherapy-a-national-cancer-database-analysis
#9
Tejan P Diwanji, Jason K Molitoris, Arpit M Chhabra, James W Snider, Soren M Bentzen, Katherine H Tkaczuk, Paula Y Rosenblatt, Susan B Kesmodel, Emily C Bellavance, Randi J Cohen, Sally B Cheston, Elizabeth M Nichols, Steven J Feigenberg
PURPOSE: Results from four major hypofractionated whole-breast radiotherapy (HF-WBRT) trials have demonstrated equivalence in select patients with early-stage breast cancer when compared with conventionally fractionated WBRT (CF-WBRT). Because relatively little data were available on patients receiving neoadjuvant or adjuvant chemotherapy, consensus guidelines published in 2011 did not endorse the use of HF-WBRT in this population. Our goal is to evaluate trends in utilization of HF-WBRT in patients receiving chemotherapy...
June 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28639029/cox2-induction-a-mechanism-of-endocrine-breast-cancer-resistance
#10
Brandi L Clark, Michael A Murphy, Landry K Kamdem
PURPOSE: Urine prostaglandin E2 (PGE2) levels have shown to be a risk factor of breast cancer, and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is known to be beneficial in preventing breast cancer risk and/or recurrence with or without aromatase inhibitors. We hypothesized that the use of an aromatase inhibitor triggers the activation of the inflammatory pathway via release of PGE2. METHODS: A single oral 25 mg dose of an aromatase inhibitor (exemestane) was given to 14 healthy postmenopausal female volunteers...
June 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28639028/erratum-to-breast-cancer-risk-models-a-comprehensive-overview-of-existing-models-validation-and-clinical-applications
#11
Jessica A Cintolo-Gonzalez, Danielle Braun, Amanda L Blackford, Emanuele Mazzola, Ahmet Acar, Jennifer K Plichta, Molly Griffin, Kevin S Hughes
No abstract text is available yet for this article.
June 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28634720/the-financial-impact-and-drivers-of-hospital-charges-in-contralateral-prophylactic-mastectomy-and-reconstruction-a-nationwide-inpatient-sample-hospital-analysis
#12
Alexandra Bucknor, Anmol Chattha, Klaas Ultee, Winona Wu, Parisa Kamali, Patrick Bletsis, Austin Chen, Bernard T Lee, Claire Cronin, Samuel J Lin
PURPOSE: Rates of contralateral prophylactic mastectomy (CPM) have increased over the last decade; it is important for surgeons and hospital systems to understand the economic drivers of increased costs in these patients. This study aims to identify factors affecting charges in those undergoing CPM and reconstruction. METHODS: Analysis of the Healthcare Cost and Utilization Project National Inpatient Sample was undertaken (2009-2012), identifying women aged ≥18 with unilateral breast cancer undergoing unilateral mastectomy with CPM and immediate breast reconstruction (IBR) (CPM group), in addition to unilateral mastectomy and IBR alone (UM group)...
June 20, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28624978/preferences-for-breast-cancer-risk-reduction-among-brca1-brca2-mutation-carriers-a-discrete-choice-experiment
#13
Alexander Liede, Carol A Mansfield, Kelly A Metcalfe, Melanie A Price, Carrie Snyder, Henry T Lynch, Sue Friedman, Justyna Amelio, Joshua Posner, Steven A Narod, Geoffrey J Lindeman, D Gareth Evans
PURPOSE: Unaffected women who carry BRCA1 or BRCA2 mutations face difficult choices about reducing their breast cancer risk. Understanding their treatment preferences could help us improve patient counseling and inform drug trials. The objective was to explore preferences for various risk-reducing options among women with germline BRCA1/2 mutations using a discrete-choice experiment survey and to compare expressed preferences with actual behaviors. METHODS: A discrete-choice experiment survey was designed wherein women choose between hypothetical treatments to reduce breast cancer risk...
June 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28624977/interaction-of-mammographic-breast-density-with-menopausal-status-and-postmenopausal-hormone-use-in-relation-to-the-risk-of-aggressive-breast-cancer-subtypes
#14
Lusine Yaghjyan, Rulla M Tamimi, Kimberly A Bertrand, Christopher G Scott, Matthew R Jensen, V Shane Pankratz, Kathy Brandt, Daniel Visscher, Aaron Norman, Fergus Couch, John Shepherd, Bo Fan, Yunn-Yi Chen, Lin Ma, Andrew H Beck, Steven R Cummings, Karla Kerlikowske, Celine M Vachon
PURPOSE: We examined the associations of mammographic breast density with breast cancer risk by tumor aggressiveness and by menopausal status and current postmenopausal hormone therapy. METHODS: This study included 2596 invasive breast cancer cases and 4059 controls selected from participants of four nested case-control studies within four established cohorts: the Mayo Mammography Health Study, the Nurses' Health Study, Nurses' Health Study II, and San Francisco Mammography Registry...
June 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28623430/a-phase-i-ii-study-of-suberoylanilide-hydroxamic-acid-saha-in-combination-with-trastuzumab-herceptin-in-patients-with-advanced-metastatic-and-or-local-chest-wall-recurrent-her2-amplified-breast-cancer-a-trial-of-the-ecog-acrin-cancer-research-group-e1104
#15
Lori J Goldstein, Fengmin Zhao, Molin Wang, Ramona F Swaby, Joseph A Sparano, Neal J Meropol, Kapil N Bhalla, Christine M Pellegrino, R Katherine Alpaugh, Carla I Falkson, Paula Klein, George W Sledge
PURPOSE: Suberoylanilide hydroxamic acid (SAHA; vorinostat), a small molecule inhibitor of histone deacetylase, attenuates signaling pathways known to confer trastuzumab resistance. A combination of SAHA and trastuzumab may be a promising strategy to improve the efficacy of trastuzumab against breast cancer. In this Phase I/II study, we evaluated the toxicity and response rate after treatment with SAHA and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with trastuzumab-resistant progressive disease...
June 16, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28616768/antitumor-activity-and-safety-profile-of-weekly-carboplatin-plus-paclitaxel-in-metastatic-breast-cancer-a-ten-year-monocentric-retrospective-study
#16
Claudio Vernieri, Monica Milano, Alessia Mennitto, Claudia Maggi, Benvenuto Ferrari, Lucia Rinaldi, Roberta Mennitto, Claudia Stefanetti, Barbara Re, Gabriella Mariani, Giulia Bianchi, Giuseppe Capri, Filippo de Braud
BACKGROUND: Taxanes are a mainstay in the treatment of metastatic breast cancer (mBC). Combination chemotherapy, including platinum-taxens doublets, can improve tumor responses and progression-free survival (PFS), but is associated with more toxicities and an uncertain benefit in terms of overall survival (OS). METHODS: We performed a retrospective study on 274 consecutive patients with mBC treated at the Division of Medical Oncology of Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, during the decade 2007-2016 with the combination of carboplatin AUC 2 plus paclitaxel 80 mg/m(2), both given on days 1 and 8 in every 21-day cycle...
June 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28612228/pleomorphic-lobular-carcinoma-in-situ-of-the-breast-a-single-institution-experience-with-clinical-follow-up-and-centralized-pathology-review
#17
Marina De Brot, Starr Koslow Mautner, Shirin Muhsen, Victor P Andrade, Anita Mamtani, Melissa Murray, Dilip Giri, Rita A Sakr, Edi Brogi, Tari A King
PURPOSE: The natural history of pleomorphic lobular carcinoma in situ (PLCIS) remains largely unknown. METHODS: A pathology database search (1995-2012) was performed to identify patients diagnosed with an LCIS variant. Patients with synchronous breast cancer and/or no evidence of pleomorphism were excluded. Original slides were re-evaluated by three pathologists to identify a consensus cohort of PLCIS. Borderline lesions with focal atypia were classified as LCIS with pleomorphic features (LCIS-PF)...
June 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28612227/development-of-a-ki-67-based-clinical-trial-assay-for-neoadjuvant-endocrine-therapy-response-monitoring-in-breast-cancer
#18
Rodrigo Goncalves, Katherine DeSchryver, Cynthia Ma, Yu Tao, Jeremy Hoog, Maggie Cheang, Erika Crouch, Neha Dahiya, Souzan Sanati, Michael Barnes, Luis Otávio Zanatta Sarian, John Olson, Donald Craig Allred, Matthew J Ellis
PURPOSE: The recent publication of the ACOSOG Z1031 trial results demonstrated that Ki-67 proliferation marker-based neoadjuvant endocrine therapy response monitoring could be used for tailoring the use of adjuvant chemotherapy in ER+HER2-negative breast cancer patients. In this paper, we describe the development of the Ki-67 clinical trial assay used for this study. METHODS: Ki-67 assay assessment focused on reproducing a 2.7% Ki-67 cut-point (CP) required for calculating the Preoperative Endocrine Prognostic Index and a 10% CP for poor endocrine therapy response identification within the first month of neoadjuvant endocrine treatment...
June 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28612226/iris-study-a-phase-ii-study-of-the-steroid-sulfatase-inhibitor-irosustat-when-added-to-an-aromatase-inhibitor-in-er-positive-breast-cancer-patients
#19
Carlo Palmieri, Rob C Stein, Xinxue Liu, Emma Hudson, Hanna Nicholas, Hironobu Sasano, Fouzia Guestini, Chris Holcombe, Sophie Barrett, Laura Kenny, Sadie Reed, Adrian Lim, Larry Hayward, Sacha Howell, R Charles Coombes
PURPOSE: Irosustat is a first-generation, orally active, irreversible steroid sulfatase inhibitor. We performed a multicentre, open label phase II trial of the addition of Irosustat to a first-line aromatase inhibitor (AI) in patients with advanced BC to evaluate the safety of the combination and to test the hypothesis that the addition of Irosustat to AI may further suppress estradiol levels and result in clinical benefit. EXPERIMENTAL DESIGN: Postmenopausal women with ER-positive locally advanced or metastatic breast cancer who had derived clinical benefit from a first-line AI and who subsequently progressed were enrolled...
June 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28612225/prolonged-survival-in-patients-with-breast-cancer-and-a-history-of-brain-metastases-results-of-a-preplanned-subgroup-analysis-from-the-randomized-phase-iii-beacon-trial
#20
Javier Cortés, Hope S Rugo, Ahmad Awada, Chris Twelves, Edith A Perez, Seock-Ah Im, Patricia Gómez-Pardo, Lee S Schwartzberg, Veronique Diéras, Denise A Yardley, David A Potter, Audrey Mailliez, Alvaro Moreno-Aspitia, Jin-Seok Ahn, Carol Zhao, Ute Hoch, Mary Tagliaferri, Alison L Hannah, Joyce O'Shaughnessy
PURPOSE: Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. METHODS: The phase 3 BEACON trial enrolled 852 women with heavily pretreated locally recurrent or metastatic breast cancer between 2011 and 2013...
June 13, 2017: Breast Cancer Research and Treatment
journal
journal
28253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"